- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Harvoni Shows Success Against Uncommon HCV Variants
A treatment approved for the most common form of hepatitis C in the US was also highly effective in less widespread variants, researchers reported at the European Association for the Study of the Liver annual meeting.
A treatment approved for the most common form of hepatitis C (HCV) in the US was also highly effective in less widespread variants, researchers reported.
The 2-drug single-pill combination of sofosbuvir and ledipasvir (Harvoni) is indicated in the U.S. for genotype 1 HCV infection, noted Armand Abergel, MD, PhD, of the Hopital d'Estaing in Clermont-Ferrand, France, and colleagues.
But in an open-label study among patients with genotypes 4 and 5 disease, the combination yielded efficacy results that were similar to those seen in genotype 1, Dr Abergel reported in a plenary session at the European Association for the Study of the Liver annual meeting.
Read more at MedPage Today: http://bit.ly/1b6xuWA
Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases
January 28th 2025First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.
Read More
